The impact of the COVID-19 pandemic on cancer care including innovations implemented in Sub-Saharan Africa: A systematic review.
Journal
Journal of global health
ISSN: 2047-2986
Titre abrégé: J Glob Health
Pays: Scotland
ID NLM: 101578780
Informations de publication
Date de publication:
17 Nov 2023
17 Nov 2023
Historique:
medline:
20
11
2023
pubmed:
17
11
2023
entrez:
17
11
2023
Statut:
epublish
Résumé
The coronavirus 2019 (COVID-19) pandemic has caused disruptions in the delivery and utilisation of cancer services. The impact of these interruptions is disproportionately borne by low- and middle-income countries in Sub-Saharan Africa (SSA). There are speculations of increased late-stage presentation and mortality as services are returning to the pre-pandemic state. This review aims to explore the extent to which the COVID-19 pandemic impacted cancer services across SSA and to identify innovations implemented across SSA to mitigate the impacts. Using database-specific search strategies, a systematic literature search was conducted in PubMed, Ovid (MedLine), Web of Science, and African Index Medicus. Eligible studies included original research, reports, perspectives and summaries of national or regional outcomes published in the English language. The primary outcome was changes in the delivery and utilisation of cancer prevention and screening, diagnosis, treatment and follow-up services. The secondary outcome was to identify implemented innovations to mitigate the impact of the pandemic on service delivery. Out of the 167 articles identified in the literature search, 46 were included in the synthesis. A majority (95.7%) of the included articles described suspension and/or delay of screening, diagnosis, and treatment services, although two studies (4.3%) described the continuation of services despite the lockdown. Care was additionally impacted by transportation limitations, shortages of staff and personal protective equipment, disruption of the medication supply chain and patients' fears and stigma associated with contracting COVID-19. A major innovation was the use of telemedicine and virtual platforms for patient consultation and follow-up during the pandemic in SSA. Furthermore, drones and mobile applications were used for sample collection, medication delivery and scheduling of treatment. In some instances, medication routes and treatment protocols were changed. The delivery and utilisation of cancer services decreased substantially during the pandemic. Cancer centres initiated innovative methods of care delivery, including telehealth and drone use, with long-term potential to mitigate the impact of the pandemic on service delivery. Cancer centres in SSA must explore sustainable, facility or country-specific innovations as services return to the pre-pandemic state. The review was registered in PROSPERO with registration number CRD42022351455.
Sections du résumé
Background
UNASSIGNED
The coronavirus 2019 (COVID-19) pandemic has caused disruptions in the delivery and utilisation of cancer services. The impact of these interruptions is disproportionately borne by low- and middle-income countries in Sub-Saharan Africa (SSA). There are speculations of increased late-stage presentation and mortality as services are returning to the pre-pandemic state. This review aims to explore the extent to which the COVID-19 pandemic impacted cancer services across SSA and to identify innovations implemented across SSA to mitigate the impacts.
Methods
UNASSIGNED
Using database-specific search strategies, a systematic literature search was conducted in PubMed, Ovid (MedLine), Web of Science, and African Index Medicus. Eligible studies included original research, reports, perspectives and summaries of national or regional outcomes published in the English language. The primary outcome was changes in the delivery and utilisation of cancer prevention and screening, diagnosis, treatment and follow-up services. The secondary outcome was to identify implemented innovations to mitigate the impact of the pandemic on service delivery.
Results
UNASSIGNED
Out of the 167 articles identified in the literature search, 46 were included in the synthesis. A majority (95.7%) of the included articles described suspension and/or delay of screening, diagnosis, and treatment services, although two studies (4.3%) described the continuation of services despite the lockdown. Care was additionally impacted by transportation limitations, shortages of staff and personal protective equipment, disruption of the medication supply chain and patients' fears and stigma associated with contracting COVID-19. A major innovation was the use of telemedicine and virtual platforms for patient consultation and follow-up during the pandemic in SSA. Furthermore, drones and mobile applications were used for sample collection, medication delivery and scheduling of treatment. In some instances, medication routes and treatment protocols were changed.
Conclusions
UNASSIGNED
The delivery and utilisation of cancer services decreased substantially during the pandemic. Cancer centres initiated innovative methods of care delivery, including telehealth and drone use, with long-term potential to mitigate the impact of the pandemic on service delivery. Cancer centres in SSA must explore sustainable, facility or country-specific innovations as services return to the pre-pandemic state.
Registration
UNASSIGNED
The review was registered in PROSPERO with registration number CRD42022351455.
Identifiants
pubmed: 37976409
doi: 10.7189/jogh.13.06048
pmc: PMC10656081
doi:
Types de publication
Systematic Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
06048Informations de copyright
Copyright © 2023 by the Journal of Global Health. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure of interest: The authors completed the ICMJE Disclosure of Interest Form (available upon request from the corresponding author) and declare that KMB receives grants from the cancer centre at the Medical College of Wisconsin.
Références
PLoS One. 2022 Nov 23;17(11):e0276517
pubmed: 36417344
J Glob Health. 2021 Dec 25;11:05024
pubmed: 35047184
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
BMJ Open. 2020 Nov 17;10(11):e043828
pubmed: 33203640
JCO Glob Oncol. 2021 Mar;7:410-415
pubmed: 33760639
JCO Glob Oncol. 2021 Mar;7:368-377
pubmed: 33689484
Front Public Health. 2022 Jan 10;9:748910
pubmed: 35083187
Br J Surg. 2020 Oct;107(11):1440-1449
pubmed: 32395848
Pan Afr Med J. 2021 Feb 05;38:131
pubmed: 33912301
Ecancermedicalscience. 2020 Apr 20;14:ed99
pubmed: 32346393
Hum Behav Emerg Technol. 2021 Dec;3(5):843-853
pubmed: 34901772
Int J Environ Res Public Health. 2007 Jun;4(2):93-100
pubmed: 17617671
Pan Afr Med J. 2021 Jun 25;39:149
pubmed: 34527165
Ecancermedicalscience. 2020 Apr 01;14:ed97
pubmed: 32269597
JMIR Mhealth Uhealth. 2021 Jan 26;9(1):e22061
pubmed: 33496672
Pan Afr Med J. 2020 Jul 06;36:153
pubmed: 32874417
JCO Glob Oncol. 2020 Apr;6:667-678
pubmed: 32343628
Ecancermedicalscience. 2020 Jul 17;14:1075
pubmed: 32863869
JCO Glob Oncol. 2022 May;8:e2100372
pubmed: 35594499
PLoS One. 2021 Mar 15;16(3):e0248281
pubmed: 33720975
Nutr Cancer. 2022;74(2):605-612
pubmed: 33899611
J Geriatr Oncol. 2021 Sep;12(7):1118-1121
pubmed: 33707048
Pan Afr Med J. 2020 Aug 11;35(Suppl 2):143
pubmed: 33193958
BMC Health Serv Res. 2021 Aug 18;21(1):831
pubmed: 34404419
S Afr Med J. 2020 Jul 28;110(9):916-919
pubmed: 32880278
Int J Cancer. 2021 Jul 1;149(1):97-107
pubmed: 33533501
Lancet Oncol. 2021 Jul;22(7):970-976
pubmed: 34051879
J Glob Health. 2021 Mar 01;11:03044
pubmed: 33763214
JCO Glob Oncol. 2020 Sep;6:1428-1438
pubmed: 32986516
S Afr Med J. 2021 May 10;111(7):685-688
pubmed: 34382554
Am J Clin Oncol. 2020 Jun;43(6):452-455
pubmed: 32304435
JAMA. 2022 Jun 21;327(23):2280
pubmed: 35727269
Int J Cancer. 2022 May 1;150(9):1497-1503
pubmed: 34927724
JCO Glob Oncol. 2020 Nov;6:1696-1703
pubmed: 33156717
Front Public Health. 2022 Mar 21;10:802947
pubmed: 35387182
S Afr Med J. 2020 Aug 31;110(9):910-915
pubmed: 32880277
Glob Health Sci Pract. 2013 Aug 14;1(2):249-61
pubmed: 25276537
Euro Surveill. 2020 May;25(19):
pubmed: 32431288
Int J Radiat Oncol Biol Phys. 2020 Oct 1;108(2):374-378
pubmed: 32890516
Lancet Oncol. 2020 Aug;21(8):1023-1034
pubmed: 32702310
Int J Cancer. 2021 Sep 15;149(6):1399-1400
pubmed: 33913167
JCO Glob Oncol. 2023 Feb;9:e2200218
pubmed: 36795990
J Glob Health. 2021 Apr 17;11:03067
pubmed: 33884189
Am Health Drug Benefits. 2020 May;13(2):85-86
pubmed: 32724503
Vaccines (Basel). 2018 Sep 08;6(3):
pubmed: 30205561
J Cancer Policy. 2020 Sep;25:100247
pubmed: 32834996
Cancer Control. 2021 Jan-Dec;28:10732748211024239
pubmed: 34152224
Ethics Med Public Health. 2020 Jul-Sep;14:100550
pubmed: 32835064
S Afr Med J. 2021 May 10;111(6):570-574
pubmed: 34382569
Int J Gynecol Cancer. 2021 Aug;31(8):1184-1185
pubmed: 34016700
Cancer. 2021 Dec 15;127(24):4711-4712
pubmed: 34424536
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
Lancet Oncol. 2022 Jun;23(6):e251-e312
pubmed: 35550267
BMJ Glob Health. 2021 Jun;6(6):
pubmed: 34183330
Lancet Oncol. 2020 May;21(5):621-622
pubmed: 32251623
Int J Gynecol Cancer. 2021 Sep;31(9):1297-1298
pubmed: 33712454
Int J Telemed Appl. 2023 May 3;2023:1487245
pubmed: 37180825
JCO Glob Oncol. 2021 Apr;7:453-454
pubmed: 33822642
Ecancermedicalscience. 2021 Jan 14;15:1170
pubmed: 33680084
Ecancermedicalscience. 2020 May 28;14:1051
pubmed: 32565904
Asia Pac J Public Health. 2020 Jul;32(5):287-288
pubmed: 32589060
PLoS One. 2021 Aug 27;16(8):e0256330
pubmed: 34449773
Ann Glob Health. 2022 May 10;88(1):29
pubmed: 35646616
N Engl J Med. 2020 Jun 11;382(24):2368-2371
pubmed: 32302076
Cancer. 2021 Aug 15;127(16):3029-3030
pubmed: 34086348
Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med. 2021 Jun;29(Special Issue):813-817
pubmed: 34327969
Clin Otolaryngol. 2021 Jul;46(4):689-691
pubmed: 33872469
Int J Equity Health. 2021 Jan 7;20(1):21
pubmed: 33413442
BMJ Open. 2021 Mar 16;11(3):e045343
pubmed: 33727273
J Infect Dev Ctries. 2020 Sep 30;14(9):994-1000
pubmed: 33031087
Nurs Educ Perspect. 2021 Nov-Dec 01;42(6):E194-E196
pubmed: 33935242
Pan Afr Med J. 2020 Aug 10;35(Suppl 2):140
pubmed: 33193955
Science. 2021 Jan 1;371(6524):25-27
pubmed: 33384363
JCO Glob Oncol. 2022 Feb;8:e2100244
pubmed: 35157511
Health Aff (Millwood). 2017 Nov;36(11):1866-1875
pubmed: 29137514